Glaxosmithkline Pharmaceutical Q2 Results
- BSE: 500660
- NSE: GLAXO
- ISIN: INE159A01016
- Sector: Biotechnology & Drugs
BSE
3,238.00
-128.50 (-3.82%)
-128.50 (-3.82%)Volume2.69 K
Updated: Tue 17 Jun, 2025 | 15:29:00
NSE
3,254.00-112.80 (-3.35%)
-112.80 (-3.35%)Volume1.46 L
Updated: Tue 17 Jun, 2025 | 15:53:22
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
Note: Comparison is on QoQ basis
Quarterly - Glaxosmithkline Pharmaceutical Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 24 | Jun 24 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Revenue | 1,010.77 | 814.65 | 24.07% | 1,010.77 | N/A |
| Selling/ General/ Admin Expenses Total | 150.71 | 151.28 | -0.38% | 150.71 | N/A |
| Depreciation/ Amortization | 16.86 | 16.41 | 2.74% | 16.86 | N/A |
| Other Operating Expenses Total | 153.86 | 137.56 | 11.85% | 153.86 | N/A |
| Total Operating Expense | 701.23 | 600.52 | 16.77% | 701.23 | N/A |
| Operating Income | 309.54 | 214.13 | 44.56% | 309.54 | N/A |
| Net Income Before Taxes | 343.81 | 249.40 | 37.85% | 343.81 | N/A |
| Net Income | 252.50 | 182.33 | 38.49% | 252.50 | N/A |
| Diluted Normalized EPS | 14.47 | 10.76 | 34.48% | 14.47 | N/A |